Official Title

FREEDOM 1, A randomized, controlled, multi-center, safety and efficacy study of FCR001 cell-based therapy relative to a tacrolimus and mycophenolate-based regimen in de novo living donor renal transplant recipients, and safety in FCR001 donors

Purpose

The purpose of this study is to learn more about whether FCR001, an investigational cell therapy, can prevent the rejection of living donor kidney transplants without the need for lifelong anti-rejection drugs.

Could this study be right for you?

• Recipient age ≥ 18 years
• Donor age ≥ 18 and ≤ 60 years
• Recipient of a first kidney transplant from a living donor
• Not diagnosed with or treated for any type of cancer (donor or recipient)

Age Range

18 and up